Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2016

01-07-2016 | Original Article

Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia

Authors: L. S. Johnson, D. Patel, E. A. King, J. N. Maslow

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2016

Login to get access

Abstract

Cascade reporting (CR) involves reporting the susceptibilities of broad-spectrum agents only when the organism is resistant to more narrow-spectrum agents. The purpose of this study is to evaluate the impact of CR on antibiotic de-escalation practices and to characterize the impact of CR on clinical outcomes. CR rules were implemented in the microbiology laboratory at Atlantic Health System (AHS) in June 2013. A retrospective chart review was conducted at two community teaching hospitals in adult patients who had a blood culture positive for a Gram-negative organism susceptible to cefazolin and who were empirically treated with broad-spectrum beta-lactam (BSBL) antibiotics. De-escalation practices were compared in the pre-CR (July 2012–December 2012) and post-CR (July 2013–December 2013) periods. The primary endpoint was the percentage of patients whose BSBL agent was de-escalated to agents listed on the post-CR antibiotic susceptibility report within 48 h of the final report. Secondary endpoints include the difference in pre-CR and post-CR periods in terms of hospital length of stay, in-hospital mortality, 30-day readmission, Clostridium difficile infections, and re-initiation of a BSBL agent within 7 days. A total of 73 patients were included; 31 in the pre-CR and 42 in the post-CR period. Patients had similar baseline characteristics. Therapy was de-escalated in 48 % of pre-CR vs 71 % of post-CR patients (p = 0.043). No significant differences were observed in secondary endpoints between patients in the pre-CR and post-CR periods. CR resulted in significant improvements in de-escalation practices without affecting safety outcomes.
Literature
1.
go back to reference Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12CrossRefPubMed Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12CrossRefPubMed
2.
go back to reference Dellit TH, Owens RC, McGowan JE Jr et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed Dellit TH, Owens RC, McGowan JE Jr et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159–177CrossRefPubMed
3.
go back to reference Clinical and Laboratory Standards Institute (2014) Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. CLSI, Wayne Clinical and Laboratory Standards Institute (2014) Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. CLSI, Wayne
4.
go back to reference Brodowy BA, Guglielmo BJ, York MK et al (1989) Experience with selective reporting of susceptibility to antimicrobial agents. Am J Hosp Pharm 46:1816–1818PubMed Brodowy BA, Guglielmo BJ, York MK et al (1989) Experience with selective reporting of susceptibility to antimicrobial agents. Am J Hosp Pharm 46:1816–1818PubMed
5.
go back to reference Tan TY, McNulty C, Charlett A et al (2003) Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice. J Antimicrob Chemother 51:379–384CrossRefPubMed Tan TY, McNulty C, Charlett A et al (2003) Laboratory antibiotic susceptibility reporting and antibiotic prescribing in general practice. J Antimicrob Chemother 51:379–384CrossRefPubMed
6.
go back to reference Coupat C, Pradier C, Degand N et al (2013) Selective reporting of antibiotic susceptibility data improves the appropriateness of intended antibiotic prescriptions in urinary tract infections: a case-vignette randomised study. Eur J Clin Microbiol Infect Dis 32:627–636CrossRefPubMed Coupat C, Pradier C, Degand N et al (2013) Selective reporting of antibiotic susceptibility data improves the appropriateness of intended antibiotic prescriptions in urinary tract infections: a case-vignette randomised study. Eur J Clin Microbiol Infect Dis 32:627–636CrossRefPubMed
7.
go back to reference Cunney R, Aziz HA, Schubert D et al (2000) Interpretive reporting and selective antimicrobial susceptibility release in non-critical microbiology results. J Antimicrob Chemother 45:705–708CrossRefPubMed Cunney R, Aziz HA, Schubert D et al (2000) Interpretive reporting and selective antimicrobial susceptibility release in non-critical microbiology results. J Antimicrob Chemother 45:705–708CrossRefPubMed
8.
go back to reference McNulty CA, Lasseter GM, Charlett A et al (2011) Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother 66:1396–1404CrossRefPubMed McNulty CA, Lasseter GM, Charlett A et al (2011) Does laboratory antibiotic susceptibility reporting influence primary care prescribing in urinary tract infection and other infections? J Antimicrob Chemother 66:1396–1404CrossRefPubMed
9.
go back to reference Steffee CH, Morrell RM, Wasilauskas BL (1997) Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data. J Antimicrob Chemother 40:595–598CrossRefPubMed Steffee CH, Morrell RM, Wasilauskas BL (1997) Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data. J Antimicrob Chemother 40:595–598CrossRefPubMed
10.
go back to reference Al-Tawfiq JA, Momattin H, Al-Habboubi F et al (2015) Restrictive reporting of selected antimicrobial susceptibilities influences clinical prescribing. J Infect Public Health 8:234–241CrossRefPubMed Al-Tawfiq JA, Momattin H, Al-Habboubi F et al (2015) Restrictive reporting of selected antimicrobial susceptibilities influences clinical prescribing. J Infect Public Health 8:234–241CrossRefPubMed
11.
go back to reference Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega et al (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40CrossRefPubMed Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega et al (2014) De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 40:32–40CrossRefPubMed
Metadata
Title
Impact of microbiology cascade reporting on antibiotic de-escalation in cefazolin-susceptible Gram-negative bacteremia
Authors
L. S. Johnson
D. Patel
E. A. King
J. N. Maslow
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2016
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2645-5

Other articles of this Issue 7/2016

European Journal of Clinical Microbiology & Infectious Diseases 7/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.